Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity

AIM: To investigate the association between peripheral blood immune-inflammatory biomarkers (PBIBs), including the pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) of diabetic retinopathy (DR), to identify novel biomarkers and therapeutic targets. METHODS: This nested case-control study enrolled 228 patients with type 2 diabetes mellitus (T2DM). Based on the staging criteria outlined in the American Diabetes Association’s Position Statement on DR, patients were classified into three groups: diabetes without DR (diabetes mellitus, DM; n=75), non-proliferative DR (NPDR, n=80), and proliferative DR groups (PDR, n=73). Comprehensive clinical data, including fasting blood tests and biochemical profiles, were collected for all subjects. PIV and other PBIBs were calculated based on hematological parameters, specifically the absolute counts of neutrophils, platelets, and monocytes, along with their respective ratios to lymphocytes. Kendall’s tau-b analysis assessed the correlation between research indicators and DR severity, while Spearman analysis evaluated the associations with baseline characteristics. Ordinal logistic regression was used to evaluate the predictive performance of peripheral blood molecular markers for DR severity. RESULTS: The study included 75 patients in the DM group (41 males), aged 60.00y (interquartile range, IQR 56.00, 66.00), 80 patients in the NPDR group (44 males), aged 60.50y (IQR 57.00, 66.00), and 73 patients in the PDR group (43 males) aged 61.00y (IQR 56.50, 68.00). PBIBs, most notably PIV, showed significant intergroup differences and demonstrated positive correlations with the severity of DR (all P<0.05). PIV was also significantly positively correlated with age, duration of diabetes and hypertension, fasting blood glucose and glycated hemoglobin. Multivariable ordinal logistic regression analysis revealed that the standardized PIV had the highest odds ratio (OR) [OR=7.76, 95% confidence interval (CI): 3.92–15.36, P<0.001]. Compared to the PIV, SIRI (OR=5.07, 95%CI: 2.83–9.07, P<0.001), SII (OR=2.00, 95%CI: 1.33–3.00, P<0.001), NLR (OR=1.59, 95%CI: 1.08–2.35, P=0.019), and PLR (OR=2.11, 95%CI: 1.37–3.25, P<0.001) had lower predictive role in comparison with PIV. CONCLUSION: PIV has higher predictive value than other PBIBs, and is an independent risk factor for DR severity, serving as a novel peripheral blood molecular biomarker for assessing DR progression.

Authors

Institutions

Publication Details

Journal
International Journal of Ophthalmology
Published
2026-11-16
DOI
https://doi.org/10.18240/ijo.2026.12.13
Primary Topic
Inflammatory Biomarkers in Disease Prognosis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity

CHEN Xiao-si, Yang Yang, Xin-Yuan Zhang, Han-Yu Wu et al.
5 links
International Journal of Ophthalmology
Inflammatory Biomarkers in Disease Prognosis
article

Pan-immune-inflammation value as a novel biomarker for diabetic retinopathy severity

CHEN Xiao-si, Yang Yang, Xin-Yuan Zhang, Han-Yu Wu, Wei-Chen Yuan, Yi-Yun Zeng
article en

Abstract

AIM: To investigate the association between peripheral blood immune-inflammatory biomarkers (PBIBs), including the pan-immune-inflammation value (PIV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI) of diabetic retinopathy (DR), to identify novel biomarkers and therapeutic targets. METHODS: This nested case-control study enrolled 228 patients with type 2 diabetes mellitus (T2DM). Based on the staging criteria outlined in the American Diabetes Association’s Position Statement on DR, patients were classified into three groups: diabetes without DR (diabetes mellitus, DM; n=75), non-proliferative DR (NPDR, n=80), and proliferative DR groups (PDR, n=73). Comprehensive clinical data, including fasting blood tests and biochemical profiles, were collected for all subjects. PIV and other PBIBs were calculated based on hematological parameters, specifically the absolute counts of neutrophils, platelets, and monocytes, along with their respective ratios to lymphocytes. Kendall’s tau-b analysis assessed the correlation between research indicators and DR severity, while Spearman analysis evaluated the associations with baseline characteristics. Ordinal logistic regression was used to evaluate the predictive performance of peripheral blood molecular markers for DR severity. RESULTS: The study included 75 patients in the DM group (41 males), aged 60.00y (interquartile range, IQR 56.00, 66.00), 80 patients in the NPDR group (44 males), aged 60.50y (IQR 57.00, 66.00), and 73 patients in the PDR group (43 males) aged 61.00y (IQR 56.50, 68.00). PBIBs, most notably PIV, showed significant intergroup differences and demonstrated positive correlations with the severity of DR (all P<0.05). PIV was also significantly positively correlated with age, duration of diabetes and hypertension, fasting blood glucose and glycated hemoglobin. Multivariable ordinal logistic regression analysis revealed that the standardized PIV had the highest odds ratio (OR) [OR=7.76, 95% confidence interval (CI): 3.92–15.36, P<0.001]. Compared to the PIV, SIRI (OR=5.07, 95%CI: 2.83–9.07, P<0.001), SII (OR=2.00, 95%CI: 1.33–3.00, P<0.001), NLR (OR=1.59, 95%CI: 1.08–2.35, P=0.019), and PLR (OR=2.11, 95%CI: 1.37–3.25, P<0.001) had lower predictive role in comparison with PIV. CONCLUSION: PIV has higher predictive value than other PBIBs, and is an independent risk factor for DR severity, serving as a novel peripheral blood molecular biomarker for assessing DR progression.

International Journal of OphthalmologyVol. 19(12)
Beijing Tongren Hospital (CN)
National Science and Technology Major Project
Good health and well-being
Inflammatory Biomarkers in Disease Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon